Keywords: SGLT2; sodium-glucose cotransporter 2; SGLT2i; SGLT2 inhibitor; BDHQ; brief-type self-administered diet history questionnaire; DHQ; self-administered diet history questionnaire; GLP-1; glucagon-like peptide-1; eGFR; estimated glomerular filtration rate; B
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Streptozotocin; Insulin; Dapagliflozin; Hyperglycemia; Diabetes; Place preference;
Keywords: type 2 diabetes; sodium-glucose cotransporter 2 inhibitors; cardiovascular safety; canagliflozin; dapagliflozin; empagliflozin; diabète de type 2; inhibiteurs du cotransporteur sodium-glucose de type 2; innocuité sur le plan cardiovasculaire; canagliflo
Keywords: Diabetes mellitus tipo 2 (DM2); Cotransportador sodio-glucosa tipo 2 (SGLT2); Inhibidores del SGLT2 (iSGLT2); Dapagliflozina; Canagliflozina; Empagliflozina; GuÃas de práctica clÃnica; Red de Grupos de Estudio de la Diabetes en; Atención Primaria de l
Keywords: SGLT2 Inhibitors; Dapagliflozin; Canagliflozin; Empagliflozin; CANVAS; CREDENCE; DECLARE-TIMI 58; Cardiovascular outcomes; Nonglycemic benefit of SGLT2 inhibitors;
Keywords: dapagliflozin; dipeptidyl peptidase-4 (DPP-4) inhibitor; drug interaction; saxagliptin; sodium-glucose cotransporter 2 (SGLT-2) inhibitor;
Keywords: canagliflozin; dapagliflozin; empagliflozin; sodium-glucose co-transporter 2 inhibitor;
Keywords: Diabetes mellitus (DM); diabetic nephropathy (DN); hyperfiltration; glomerular filtration rate (GFR); proximal tubule; sodium/glucose cotransport; sodium/glucose cotransporter 2 (SGLT2); SGLT2 inhibitor; canagliflozin; dapagliflozin;
Keywords: Dapagliflozin; Glucosuria; Sodium glucose cotransporter 2; SGLT2; Urinary tract infection; UTI;
Keywords: obesity; diabetes; dyslipidemia; exenatide extended-release; dapagliflozin; canagliflozin; Icosapent ethyl;
Keywords: Dapagliflozin; Cost-effectiveness; Type 2 diabetes mellitus; Sulfonylurea; Economic modeling
Anthropometric outcomes in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective glycemic control from single center
Keywords: Anthropometric outcomes; Type 2 diabetes; Dapagliflozin; HbA1c; Body mass index; Body weight; Weight loss;
Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit
Keywords: Dapagliflozin; SGLT2 inhibitor; Genital fungal infection; Genital mycotic infection; Thrush;
Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy
Keywords: ABP; arterial blood pressure; ACE; angiotensin converting enzyme; AGEs; advanced glycation end products; ARB; angiotensin receptor blocker; BUN; blood urea nitrogen; Cr Cl; creatinine clearance; DN; diabetic nephropathy; GSH-Px; glutathione peroxidase; Hb
The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels
Keywords: Dapagliflozin; Aortic smooth muscle; Voltage-dependent K+ channel; PKG; Vasorelaxation;
Bioequivalence of Dapagliflozin/Metformin Extended-release Fixed-combination Drug Product and Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Russian Subjects
Keywords: bioequivalence; dapagliflozin; fixed-combination drug product; metformin; Russian Federation;
Dapagliflozin improves blood glucose in diabetes on triple oral hypoglycemic agents having inadequate glucose control
Keywords: Dapagliflozin; Type 2 diabetes; Insulin glargine;
Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model
Keywords: Obese insulin-resistance; Renal function; Renal organic anion transporter 3 function; Oxidative stress; Dapagliflozin;
Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study
Keywords: nonalcoholic; steatohepatitis; type 2 diabetes mellitus; sodium-glucose; cotransporter 2-inhibitor; dapagliflozin; open-label;
SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats
Keywords: Obese-insulin resistance; Cognitive function; Mitochondrial function; Synaptic plasticity; Dapagliflozin; Vildagliptin; HFD; high fat diet; GLP1; glucagon-like peptide 1; OFT; open field test; OGTT; oral glucose tolerance test; MWM; Morris water maze; HDL
Effects of phosphate binders on the gastrointestinal absorption of arsenate and of an SGLT2 inhibitor drug on the urinary excretion of arsenite in mice
Keywords: Arsenic; Aluminium hydroxide; Lanthanum carbonate; Sevelamer; Dapagliflozin; SGLT2;
EMPA-REG OUTCOME: The Nephrologist's Point of View
Keywords: Canagliflozin; Dapagliflozin; Empagliflozin; Renal outcomes; Renoprotection; Sodium glucose cotransporter 2 inhibitors;
The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes
Keywords: Bone microarchitecture; Cortical bone; Trabecular bone; Glycosuria; Hypercalciuria; Canagliflozin; Dapagliflozin;
Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels
Keywords: Dapagliflozin; Dyslipidemia; Type II diabetes mellitus; SGLT2 inhibitors; Cardiovascular;
Early drug use of dapagliflozin prescribed by general practitioners and diabetologists in Germany
Keywords: Dapagliflozin; Diabetes; Anti-diabetic;
Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus
Keywords: SGLT2 inhibitors; Dapagliflozin; Canagliflozin; Empagliflozin; Metformin; Type 2 diabetes mellitus; HbA1c;
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure
Keywords: Dapagliflozin; Type 2 diabetes mellitus; Heart failure; Pooled analysis; Cardiovascular safety; Efficacy;
Resolving the KgA1c paradox in the management of type 2 diabetes mellitus
Keywords: Canagliflozin; Dapagliflozin; Empagliflozin; KgA1c paradox; Overweight; SGLT2 inhibitors; Type 2 diabetes mellitus;
Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice
Keywords: Dapagliflozin; Diabetes; Glucose-dependent insulinotropic polypeptide (GIP); Insulin secretion; SGLT2 inhibitor;
Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects
Keywords: bioequivalence; dapagliflozin; fixed-dose combination; metformin extended release; SGLT2 inhibitor; type 2 diabetes mellitus;
Bioequivalence and food effect of heat-stressed and nonâ¿¿heat-stressed dapagliflozin 2.5- and 10-mg tablets
Keywords: AUC0â¿¿t; area under the plasma concentrationâ¿¿time curve from time 0 to the last quantifiable concentration; AUC0â¿¿inf; area under the plasma concentrationâ¿¿time curve from time 0 to infinity; Cp; plasma concentration; Cmax; maximum Cp; Dapagliflozin;
SGLT2 inhibitors: their potential reduction in blood pressure
Keywords: Canagliflozin; dapagliflozin; empagliflozin; hypertension
Dapagliflozina: Más allá del control glucémico en el tratamiento de la diabetes mellitus tipo 2
Keywords: Diabetes mellitus tipo 2; Dapagliflozina; Riesgo cardiovascularType 2 diabetes mellitus; Dapagliflozin; Cardiovascular risk
Análisis de coste-efectividad de dapagliflozina en comparación con los inhibidores de la DPP4 y otros antidiabéticos orales en el tratamiento de la diabetes mellitus tipo 2 en España
Keywords: Diabetes; Costes; Dapagliflozina; Inhibidores de DPP4; Sulfonilureas; TiazolidindionasDiabetes; Costs; Dapagliflozin; DPP4 inhibitors; Sulphonylureas; Thiazolidinediones
Bioequivalence, Food Effect, and SteadyâState Assessment of Dapagliflozin/Metformin Extendedârelease Fixedâdose Combination Tablets Relative to Singleâcomponent Dapagliflozin and Metformin Extendedârelease Tablets in Healthy Subjects
Keywords: bioequivalence; dapagliflozin; metformin XR; pharmacokinetics; SGLT2 inhibitor; type 2 diabetes mellitus;
Dapagliflozin: Glucuretic action and beyond
Keywords: Dapagliflozin; SGLT2 inhibition; Diabetes mellitus; Perspectives
Zucker Diabetic Fatty rats exhibit hypercoagulability and accelerated thrombus formation in the Arterio-Venous shunt model of thrombosis
Keywords: aPTT; activated partial thromboplastin time; A-V; Arterio-Venous; Dapa; dapagliflozin; ETP; endogenous thrombin potential; FXa; coagulation factor Xa; MI; myocardial infarction; Min; minute; PRP; platelet-rich plasma; PT; prothrombin time; s; second; SD;
Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence
Keywords: Canagliflozin; Dapagliflozin; Empagliflozin; Energy balance; Glucotoxicity; Insulin secretion; Insulin sensitivity; Type 2 diabetes
The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties
Keywords: Triazolopyridinone; Hydantoin; SGLT2; Canagliflozin; Dapagliflozin; Glucoside;
Dapagliflozin as Monotherapy in Drug-Naive Asian Patients With Type 2 Diabetes Mellitus: A Randomized, Blinded, Prospective Phase III Study
Keywords: Asian; dapagliflozin; glycemic control; monotherapy; SGLT2; type 2 diabetes mellitus;
SGLT2 inhibitors in the treatment of type 2 diabetes
Keywords: Type 2 diabetes; Glucose reabsorption; SGLT2 inhibitors; Dapagliflozin; Canagliflozin; EmpagliflozinHbA1c, hemoglobin A1c; FRG, familial renal glucosuria; GLUT, glucose transporter; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose;
Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin
Keywords: balanitis; dapagliflozin; genital infection; glucosuria; sodium-glucose cotransporter 2; SGLT2; vulvovaginitis;
Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the renal sodium glucose co-transporter 2
Keywords: Dapagliflozin; Occupational exposure limit; Pharmacokinetics; SGLT2 inhibitors; Urinary glucose excretion;
Pharmacokinetic and Pharmacodynamic Properties of Single- and Multiple-Dose of Dapagliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects
Keywords: Chinese; dapagliflozin; pharmacodynamics; pharmacokinetics; SGLT2; type 2 diabetes mellitus;
Exploration of SAR regarding glucose moiety in novel C-aryl glucoside inhibitors of SGLT2
Keywords: SGLT; Dapagliflozin; Thiazole; Glucose; Diabetes
Glucosides with cyclic diarylpolynoid as novel C-aryl glucoside SGLT2 inhibitors
Keywords: SGLT; Dapagliflozin; Diarylpolynoid; Glucoside; Diabetes
SGLT2 inhibitors: molecular design and potential differences in effect
Keywords: dapagliflozin; diabetes; glucosuria; insulin resistance; phlorizin; SGLT2;
Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study
Keywords: dapagliflozin; hepatic impairment; pharmacokinetics; SGLT2 inhibitors; special populations
Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents
Keywords: SGLT; Dapagliflozin; Ring-closing metathesis; Glucoside; Macrocycle;
Thiazolylmethyl ortho-substituted phenyl glucoside library as novel C-aryl glucoside SGLT2 inhibitors
Keywords: SGLT; Dapagliflozin; Thiazole; Glucoside; Diabetes